Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization
- 1 August 2002
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 54 (2) , 115-119
- https://doi.org/10.1046/j.1365-2125.2002.01632.x
Abstract
Clinical studies comparing nebulized drug delivery systems could be flawed because of the high doses used. We have compared lung and total systemic delivery of salbutamol from a nebuliser with that from a metered dose inhaler by measuring urinary recovery of drug and its sulphate metabolite. Twelve healthy volunteers provided urine samples at 0, 0.5, 1, 2, 4, 8, 12 and 24 h after the start of dosing. Formulations and doses were 5 x 100 microg oral solution (ORAL), 5 x 100 microg from a metered dose inhaler (MDI), 2.5 mg using a nebuliser (NEB) and NEB with 25 g oral charcoal (NEBC). Each study phase was separated by 7 days and the order of dosing was randomized. Mean (s.d.) 30 min urinary salbutamol excretion after ORAL, MDI, NEB and NEBC was 0.4 (0.7), 12.1 (3.7), 15.0 (3.9) and 18.2 (5.7) microg, respectively (all P<0.001 compared with ORAL). When normalized for the dose available for inhalation from MDI, NEB and NEBC, the mean (s.d.) 30 min urinary excretion of salbutamol was 2.4 (0.7), 2.9 (0.6) and 2.7 (0.6)%, respectively, with a mean ratio (90% confidence interval) between NEB and NEBC, of 95.3 (91.1, 99.5)%. The mean (s.d.) excretion of salbutamol plus its metabolite over 24 h post ORAL, MDI, NEB and NEBC dosing was 297.9 (38.3), 290.3 (41.4), 266.5 (44.6) and 151.7 (40.9) microg, respectively. The mean ratio (90% confidence interval) between MDI and ORAL, and NEB and ORAL were 97.5 (94.1, 101.0) and 90.7 (81.2, 100.2)%, respectively. The NEBC data indicate that 6.07 (1.04)% of the nominal nebulized dose was delivered to the lungs. The 30 min urinary recovery of salbutamol, an index of the relative systemic bioavailability of salbutamol following inhalation, can be used to compare the lung deposition of nebulized systems. Similarly, the urinary 24 h recovery of salbutamol plus its metabolite, an index of the relative systemic bioavailability of salbutamol following inhalation, can be used to compare the delivery of nebulized drug to the systemic circulation.Keywords
This publication has 15 references indexed in Scilit:
- Relative bioavailability of salbutamol to the lung following inhalation when administration is prolongedPublished by Wiley ,2000
- Effects of airway calibre on lung delivery of nebulised salbutamolThorax, 1997
- The science of nebulised drug deliveryThorax, 1997
- Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthmaEuropean Respiratory Journal, 1995
- Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream").Thorax, 1994
- Determination of the relative bioavailability of salbutamol to the lung following inhalation [see comments]British Journal of Clinical Pharmacology, 1992
- Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.Thorax, 1990
- Delivery of Albuterol and Ipratropium Bromide from Two Nebulizer Systems in Chronic Stable AsthmaChest, 1989
- Comparison of three techniques of inhalation on the airway response to terbutaline.Thorax, 1983
- ASSESSMENT OF JET NEBULISERS FOR LUNG AEROSOL THERAPYThe Lancet, 1983